on chromosome 22q was also observed in both carcinomas [2, 3] , but the involved gene has not yet been clarified. Candidate suppressor genes on chromosome 22q are the neurofibromatosis 2 (NF2) gene [4] and the p300 gene [5] . NF2 encodes a 595-amino-acid protein, schwannomin or merlin (moesin-ezrin-radixin-likeprotein), which exhibits significant homology to a highly conserved family of proteins involved in connecting the cytoskelton to components of plasma membranes. NF2 is considered to be a tumor suppressor gene for tumors associated with NF2 disorders (schwannoma and meningioma) and for NF2-unrelated tumors (mesothelioma, colon cancer, and gastrointestinal stromal tumor) [6] [7] [8] .
On the other hand, p300 is a transcriptional coactivator that facilitates gene expression through several mechanisms [9] , including molecular scaffolds coupling many transcriptional factors [10] , chromatin remodeling by histone acetyltransferase (HAT) activity [11] , and activation of transcription factors, such as p53 and GATA-1, by acetylation (FAT activity) [12] . p300 is a target for the adenoviral E1A oncoprotein, and bi-allelic mutations have been demonstrated in some human cancers, including colorectal carcinomas [13, 14] . Furthermore, in regard to its highly homologous protein, CBP (cAMP response element binding profein [CREB]-binding protein), it is known that patients with one mutant germline copy of CBP develop a rare, multisystem disorder, Rubinstein Taybi syndrome, one of the characteristics of which is a heightened cancer risk [15] . In the present study, we focused on the alterations on chromosome 22q to clarify its significance in the development and progression of gastric carcinoma. Detailed mapping of LOH and subsequent polymerase chain reaction (PCR)-single-stranded conformation polymorphism (SSCP) analysis demonstrated that p300 gene alteration occurs frequently in gastric carcinoma. However, the significance of the abnormalities is different in the intestinal and diffuse types of gastric carcinoma. Each subtype of gastric carcinoma exhibits
Introduction
Gastric carcinoma shares common chromosomal losses with colorectal carcinoma, such as that of 5q (30% to 40% at or near APC), 17p (over 60% at TP53), and 18q (over 60% at DCC) [1] . Loss of heterozygosity (LOH) its own clinicopathological features and is considered to develop through a different genetic pathway [1] .
Patients, materials, and methods

Tumor samples
Tumor samples consisted of 60 advanced (invasion in and beyond the muscular layer) and 20 early gastric carcinomas (intramucosal carcinoma or invasion of the submucosal layer), which were resected from 80 patients at Tokyo Metropolitan Komagome Hospital and Jichi Medical School Hospital. The corresponding normal tissues, which were located at a site remote from the carcinoma, were also obtained simultaneously. All samples were taken immediately after resection and frozen in dry ice-hexane. The resected stomach was then routinely processed with hematoxylin-eosin staining for histopathological analysis. Tumor location, depth of invasion, and lymphatic or vascular invasion were determined with reference to the Japanese classification of gastric carcinoma of the Japanese Research Society for Gastric Cancer [16] . Histological subtypes of the gastric carcinoma were classified as diffuse type or intestinal type, using Laurén's criteria [17] . The presence of Epstein-Barr virus (EBV) was determined by an in situ hybridization (ISH) method targeting EBVencoded small RNA (EBER) [18] , using formalinfixed paraffin-embedded sections of the carcinoma.
LOH analysis using microsatellite markers
High-molecular weight DNA was extracted from frozen tissues, using phenol-chloroform extraction, as reported previously [19] . The DNA was then subjected to the PCR-based analyses, as described below. PCR-based analysis of LOH was performed using microsatellite markers. The primers targeted 14 microsatellites; D22S264 (22q11), D22S446 (22q11), D22S315 (22q11-12), D22S300 (22q12), NF2CA3 (22q12), D22S268 (22q12), D22S275 (22q12), D22S280 (22q12), D22S304 (22q12-13), D22S277 (22q13), IL2RB (22q12-13), D22S423 (22q13), D22S279 (22q13), and D22S274 (22q13). The sequences of the primers were obtained from the Genome Database (http://www.gdb.org/gdb/) and Ensembl Human (http://www.ensembl.org/ Homo_sapiens/) on the Internet. PCR was performed under the same conditions as those outlined in a previous study [18] . The reaction product was then denatured and electrophoresed on a 6% polyacrylamide gel containing 7 M urea. The gel was exposed to X-ray film for 48-72 h at Ϫ80°C. By comparing the electrophoresis patterns of the PCR products of the paired DNA samples of the same patient, LOH was defined as the loss of any band for the normal tissue in the tumor sample.
Reverse transcriptase-PCR (RT-PCR) and RT-PCR-SSCP
Total RNA was extracted, using the acid guanidium method, from 33 advanced gastric carcinomas and five normal tissues of the stomach mucosa. All carcinomas were advanced ones, because of the limitation of the amount of the tissue available for RNA study. Isolated RNA was reverse-transcribed to cDNA, using the Ready To GO kit (Amersham Pharmacia Biotech, Uppsala, Sweden). The coding region of the p300 gene between codons 111 and 1832 (71% of the p300 gene) was divided into 16 regions, each of which was amplified by each specific primer pair, as described previously [13] . Then, the amplified products were separated overnight at 6-8 W on 6% non-denaturing polyacrylamide gels containing 6% glycerol.
Sequencing analysis
The shifted bands were excised from the SSCP gel and subjected to DNA extraction. The extracted DNA was amplified by PCR, using the same conditions as for the RT-PCR-SSCP. DNA sequencing of PCR products was carried out using an ABI PRISM TM dRhodamine Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Chiba, Japan) and an ABI PRISM TM 377 DNA Sequencer.
Statistical analysis
Statistical analysis was performed using Fisher's exact probability test, the 2 test for independence, the Kruskal-Wallis rank test, and the Mann-Whitney Utest. A P value of Ͻ0.05 was considered significant.
Results
PCR evaluation of LOH using microsatellite markers
Fourteen microsatellite markers were first used to evaluate the LOH on chromosome arm 22q in gastric carcinoma. Sixty cases of advanced gastric carcinoma (36 diffuse type and 24 intestinal type) were examined, because only a limited amount of DNA was available from the early carcinomas.
All of these microsatellite loci showed LOH at various frequencies (Fig. 1) , but the loci that showed LOH of more than 30% were D22S275 (14 of 43 informative cases; 33%), D22S277 (21/59; 36%), D22S304 (21/56; 38%), and IL2RB (27/59; 46%). Thus, the most fre-quent LOH was located at the 22q13 locus containing the p300 gene, which was telomeric to the NF2 gene.
Clinicopathological significance of 22q13-LOH
To clarify the significance of 22q13-LOH in the development and progression of gastric carcinoma, we further examined 20 more cases of early carcinoma (10 diffuse and 10 intestinal type). Using three microsatellite markers, D22S304, D22S277, and IL2RB ( Fig. 1) , the frequency of LOH on these loci was significantly lower in the early carcinomas, at 26% (5/19 informative cases), 15% (3/20) , and 0%, respectively, than in the advanced cases (36%, 38% and 46%, respectively).
When the data for the early and advanced gastric carcinomas were combined, we could evaluate the clinicopathological characteristics of the patients whose specimens showed LOH on any of the three loci of 22q13 ( Table 1 ). The frequency of 22q13-LOH was the same in the diffuse (30/46) and intestinal types (21/34). In the diffuse type, 22q13-LOH was not correlated with any of the clinicopathological factors. On the other hand, in the intestinal type, 22q13-LOH was more frequent in the carcinomas of advanced stage, showing vascular and lymphatic invasion and lymph node metastasis. As for the association with EBV, a positive signal for EBER was much more frequently observed in the diffuse type, but the frequency of 22q13-LOH was not significantly different in the carcinomas with or without EBV in either the intestinal or the diffuse types.
Sequence analysis of p300 cDNA
Because p300 is located on chromosome 22q13, we evaluated the somatic mutation of the p300 gene by RT-PCR and SSCP techniques. The specimens examined consisted of 27 carcinomas showing 22q13-LOH (14 diffuse type and 13 intestinal type), and 6 carcinomas without LOH (4 diffuse and 2 intestinal type). All carcinomas were advanced ones, because of the limitation of the amount of tissue available for RNA study.
Twelve mutations were identified in ten samples (Fig. 2) , consisting of four cases of diffuse type and six cases of intestinal type of gastric carcinoma (Table 2) . There was no significant correlation of the mutation with clinicopathological factors such as age, sex, or location, although there was a significant correlation with the histological type.
Nine mutations were point mutations: seven were transition and two were transversion type mutations. The other three mutations were frameshift mutations, which resulted in the generation of a stop codon. Five point mutations and one frameshift mutation in cases 8, 25, 39 and 47 were within the first and second Cys/Hisrich regions (C/H-1 and -2) encoded by the p300 gene. One deletion mutation, in case 37, occurred in the bromodomain (Br) and the two point mutations in cases 41 and 57 were within the CREB-binding domain.
Regarding alteration of the other allele, mutation of the p300 gene was only identified in 1 of the 14 cases of the diffuse type of gastric carcinoma with 22q13- LOH   Fig. 1A,B . Evaluation of loss of heterozygosity (LOH) on chromosome 22q in gastric carcinoma. A LOH analysis using microsatellite markers. LOH was evaluated by comparing the electrophoresis patterns of the amplified fragments of microsatellite markers, using DNA samples of carcinomas (T) and corresponding normal tissue (N). LOH was defined as the loss of any band of non-neoplastic tissue in the carcinoma, such as LOHs (arrowheads) on D22S304, D22S277, and IL2RB. Cases 3, 8, 10, and 37, advanced carcinomas. Case 61, early carcinoma. B The frequency of loss of heterozygosity (LOH) on chromosome arm 22q in advanced carcinomas. A high frequency of LOH, of more than 30%, is observed on D22S275 (33%), D22S304 (38%), D22S277 (36%), and IL2RB (46%). The location of D22S304, D22S277, and IL2RB is close to the p300 gene locus on chromosome arm 22q13 (7%), whereas it was observed in 6 of the 13 cases of the intestinal type with LOH (46%). In the cases without 22q13-LOH, three mutations were identified, and all of the cases with the mutation were of the diffuse type histologically. Two of the three mutations were frameshift mutations, and two of the three cases were associated with EBV infection.
Discussion
Gastric carcinoma has the same alterations of tumor suppressor genes as colorectal carcinoma, such as APC on chromosome 5q, TP53 on 17p, and DCC on 18q. In the present study, we confirmed that LOH on chromosome 22q was also observed with the same considerable A fragment of p300 gene cDNA was amplified and subjected to PCR-SSCP anaysis; 300M corresponds to the region between codons 1378 and 1477 in case 3; 300C, region between codons 327 and 443 in case 8; and 300J, region between codons 1060 and 1173 in case 37. The sequencing of the abnormally shifted bands (arrowheads) demonstrates 1 base-pair deletion on codon 1468 in case 3, a missense mutation, GGG to GAG (Gly to Glu), on codon 359 in case 8, and 25 base-pair deletion on codon 1084 to 1092 in case 37. T and N as in Fig. 1 frequency in gastric carcinomas as in colon carcinomas [2] . A candidate for the tumor suppressor gene on chromosome 22q is the p300 gene, because the most frequent LOH was located at the 22q13 locus. When we directly analyzed the p300 gene mutations by RT-PCR-SSCP, mutations were observed in 6 of the 13 gastric carcinomas of the intestinal type with 22q13-LOH. One mutation was a frameshift mutation at codon 1084, which resulted in truncation of the encoded product before the C/H-2 ( Table 2) . C/H-2 is located within the histone acetyltransferase (HAT) domain, where p300/CBP also interacts with p53 functioning as a coactivator for p53-mediated transcription [12] . The other five mutations were missense mutations at the C/H-1 and -2, and CREB-binding domains. Thus, mutation within a functionally important region in combination with loss of another allele fits the two-hit theory of the inactivation of tumor suppressor genes. Therefore, the p300 gene is the tumor suppressor gene in the intestinal type of gastric carcinoma, and this finding also illustrates that common genetic alterations underlie colorectal carcinoma and the intestinal type of gastric carcinoma. LOH on chromosome 22q was observed mainly in the late stage of colorectal carcinomas, correlating with lymph node metastasis [20] . In the intestinal type of gastric carcinoma, 22q13-LOH was more frequently observed in the advanced stage, accompanied by vascular and lymphatic invasion, and lymph node metastasis.
Thus, the inactivation of p300 may be involved in the progression of gastric carcinoma, facilitating metastasis via vascular and lymphatic invasion. This may be related to the function of p300 other than that of histone acetyl transferase, that is, the activation of a major adhesion molecule, 1 integrin, by interacting with the nuclear protooncoprotein SYT [21] . It is also interesting to note that there were two cases that showed two different mutations in the same tumor tissue. This also suggests that the inactivation of p300 is a late genetic event in the subpopulation of the intestinal type of gastric carcinoma.
In the diffuse type of gastric carcinoma, the frequency of 22q13-LOH was similar to that in the intestinal type, but p300 gene mutation was rare in the carcinomas with LOH. Furthermore, in contrast to findings in the intestinal type, 22q13-LOH was not correlated with any of the clinicopathological factors. Therefore, the significance of p300 gene alteration in the diffuse type is apparently different from that in the intestinal type. Because two of the three mutations were frameshift mutations in the diffuse type without 22q-LOH, the alteration on at least one allele of the p300 gene may be more ubiquitous in the diffuse type. Therefore, when combined with other alterations, such as homozygous deletion, promoter methylation, and EBV infection, inactivation of p300 may occur along the carcinogenesis of the diffuse type of gastric carcinoma. Mouse embryonic cells (MEC) with a p300ϩ/Ϫ genotype showed defec- tiveness in adhesion to fibronectin-coated surfaces in comparison with the wild type, suggesting that failure to form a sufficient quantity of SYT/p300 complexes leads to a major defect in cell adhesion/spreading [21] . In addition to the example of Rubinstein Taybi syndrome in humans, mice with monoallelic inactivation of the CBP gene show an increased incidence of hematological malignancies [22] . Thus, p300 gene alteration, even on one allele (haploinsufficiency), may be involved in the development of the carcinoma. Knock-down experiments, using RNA interference, may clarify the role of p300 in gastric cancer.
In conclusion, p300 gene alteration may play an important role in both the intestinal type and the diffuse type of gastric carcinoma, but the significance of the alterations in each type is different. Mutation within a functionally important region, in combination with loss of one allele, suggests that the p300 gene is the tumor suppressor gene in the intestinal type of gastric carcinoma, as it is in colorectal carcinoma. On the other hand, in the diffuse type, the p300 gene is not a classical suppressor gene, but further study is necessary to find other mechanisms of p300 inactivation and to clarify the functional role of p300 in cell adhesion/ spreading.
